<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id><journal-title-group><journal-title>BMC Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1471-230X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24899360</article-id><article-id pub-id-type="pmc">4082414</article-id><article-id pub-id-type="publisher-id">1471-230X-14-103</article-id><article-id pub-id-type="doi">10.1186/1471-230X-14-103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A rapid, simple questionnaire to assess gastrointestinal symptoms after oral ferrous sulphate supplementation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Pereira</surname><given-names>Dora IA</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dora.pereira@mrc-hnr.cam.ac.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Couto Irving</surname><given-names>Susana S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>susana_irving@yahoo.co.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Lomer</surname><given-names>Miranda CE</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>miranda.lomer@kcl.ac.uk</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Powell</surname><given-names>Jonathan J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jonathan.powell@mrc-hnr.cam.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>MRC Human Nutrition Research, Elsie Widdowson Laboratory, CB1 9NL Cambridge, UK</aff><aff id="I2"><label>2</label>Diabetes and Nutritional Sciences Division, King&#x02019;s College London, London, UK</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>4</day><month>6</month><year>2014</year></pub-date><volume>14</volume><fpage>103</fpage><lpage>103</lpage><history><date date-type="received"><day>10</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Pereira et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Pereira et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-230X/14/103"/><abstract><sec><title>Background</title><p>Oral iron supplementation is often associated with rapid onset of gastrointestinal side-effects. The aim of this study was to develop and trial a short, simple questionnaire to capture these early side-effects and to determine which symptoms are more discriminating.</p></sec><sec><title>Methods</title><p>The study was a double-blind placebo-controlled randomized parallel trial with one week treatment followed by one week wash-out. Subjects were randomized into two treatment groups (n&#x02009;=&#x02009;10/group) to receive either ferrous sulphate (200&#x000a0;mg capsules containing 65&#x000a0;mg of iron) or placebo, both to be taken at mealtimes twice daily during the treatment period. Subjects completed the questionnaires daily for 14&#x000a0;days. The questionnaire included gastrointestinal symptoms commonly reported to be associated with the oral intake of ferrous iron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and constipation).</p></sec><sec><title>Results</title><p>Seventy five per cent of participants reporting the presence of one or more symptoms in the first week of the study were in the ferrous sulphate group. In the second week of the study (i.e. wash-out), 67% of the participants reporting one or more symptom(s) were in the ferrous sulphate group. In the first week of the study (treatment) the number of symptoms reported by participants in the ferrous sulphate group (mean&#x02009;&#x000b1;&#x02009;SEM&#x02009;=&#x02009;6.7&#x02009;&#x000b1;&#x02009;1.7) was significantly higher than that for participants in the placebo group (1.2&#x02009;&#x000b1;&#x02009;0.5) (<italic>p</italic>&#x02009;=&#x02009;0.01). In the second week of the study (wash-out) the number of symptoms reported by participants in the ferrous sulphate group (4.6&#x02009;&#x000b1;&#x02009;2.0) appeared higher than for participants in the placebo group (1.0&#x02009;&#x000b1;&#x02009;0.7) although this did not reach significance (<italic>p</italic>&#x02009;=&#x02009;0.12). Events for which the gastrointestinal symptom questionnaire was most discriminatory between ferrous sulphate and placebo groups were: heartburn, abdominal pain and the presence of black stools (all <italic>p</italic>&#x02009;&#x02264;&#x02009;0.03).</p></sec><sec><title>Conclusions</title><p>A tool for the detection of commonly-occurring side effects should not require large study numbers to be effective. With just 10 subjects per group (iron or placebo), this simple questionnaire measures gastrointestinal side-effects associated with oral iron (ferrous sulphate) supplementation, and would be appropriate for use in intervention studies or clinical trials.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT02146053">NCT02146053</ext-link> (21/05/2014).</p></sec></abstract><kwd-group><kwd>Gastrointestinal symptoms</kwd><kwd>Ferrous sulphate</kwd><kwd>Iron supplementation</kwd><kwd>Side-effects</kwd><kwd>Adverse events</kwd><kwd>Oral iron</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Despite many attempts to eradicate or even reduce iron deficiency anaemia (IDA), it remains the most prevalent nutritional deficiency disorder in the world affecting around 1.1 billion people of which nearly 400 million are children. The World Health Organization (WHO) reports that worldwide, at any given moment, more individuals have IDA than any other health problem [<xref ref-type="bibr" rid="B1">1</xref>]. Iron deficiency anaemia accounts for 2.4% of the global disease burden and it occupies the World Health Organization (WHO) top ten hit list of targeted global health problems [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>].</p><p>One of the hurdles to eradicate this disorder has been the use of iron preparations, typically ferrous iron salts 65 mg<sub>Fe</sub> 2&#x02013;3 times daily [<xref ref-type="bibr" rid="B4">4</xref>], that risk significant gastrointestinal disturbances [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B10">10</xref>] and systemic infection [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Data from the National Health Service shows that at least 97.5% of the prescriptions filled for oral iron in England alone are for simple ferrous salts (sulphate, fumarate or gluconate) [<xref ref-type="bibr" rid="B15">15</xref>]. In the main, gastrointestinal side-effects start to present early in the treatment course [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] albeit onset of symptoms and severity must be related to the iron dosage and the posology followed (i.e. weekly or daily) [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. Reasons for gastrointestinal disturbance are well described: even in subjects with IDA only about 20-30% of oral supplemented iron is absorbed, while the remainder transits through the gut lumen inducing (a) free radical mediated damage to the gut mucosa [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>] and (b) undesirable changes to colonic microflora [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. Gastrointestinal symptoms impact on the general wellbeing of individuals [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B37">37</xref>] and are known to affect compliance with oral iron therapy and, therefore, treatment efficacy [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B40">40</xref>].</p><p>Self-reporting questionnaires may be used to monitor gastrointestinal symptoms in disease-specific scenarios [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B41">41</xref>-<xref ref-type="bibr" rid="B44">44</xref>], although only a few have been formally tested [<xref ref-type="bibr" rid="B36">36</xref>], but there is currently no gastrointestinal-specific questionnaire to identify oral iron-induced symptoms in healthy subjects [<xref ref-type="bibr" rid="B45">45</xref>]. The current study presents a simple one-page gastrointestinal symptom questionnaire (a) to capture the early side-effects normally associated with oral iron (ferrous sulphate) supplementation and (b) to determine which symptoms are more discriminant. Since gastrointestinal side effects, following oral iron, are reportedly so common, any robust questionnaire should be valid in just a small number of subjects. With just 10 subjects per group (iron or placebo), this questionnaire is shown to be a useful instrument to measure gastrointestinal side-effects associated with oral iron supplementation, and would thus be appropriate for use in intervention studies or clinical trials.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Gastrointestinal symptom questionnaire</title><p>Questions for the gastrointestinal symptom questionnaire (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>) were based on previously validated bowel symptom questionnaires [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>] and included gastrointestinal symptoms commonly reported to be associated with the oral intake of ferrous iron salts: i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and constipation [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. In addition, the questionnaire included questions on breathlessness because this is common in anaemic patients and headache that, although not generally associated with oral iron therapy, is common with some gastrointestinal complaints [<xref ref-type="bibr" rid="B50">50</xref>,<xref ref-type="bibr" rid="B51">51</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>One-page symptom questionnaire to assess gastrointestinal adverse effects after oral iron supplementation.</bold> The letters &#x02018;A&#x02019; to &#x02018;J&#x02019; are not present on the actual questionnaire but are herein shown for ease of reference throughout this manuscript.</p></caption><graphic xlink:href="1471-230X-14-103-1"/></fig><p>The degree of discomfort from each symptom was ranked by the study subjects in one of four categories (absent, mild, moderate or severe) as used in previous studies [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B52">52</xref>]. The frequency of bowel movements was registered and the questionnaire included a question on whether these were normal or abnormal. Compliance with the oral iron or placebo treatment was also assessed.</p></sec><sec><title>Participants</title><p>Twenty healthy subjects, seven men and thirteen women aged 18&#x02013;65 years (average age 32), were recruited via circular email. The presence of any chronic disease, pregnancy or lactation were considered as exclusion criteria. Subjects were asked to complete a baseline questionnaire including demographic questions on age, gender, education and job title.</p><p>This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the King&#x02019;s College London (KCL) Research Ethics Committee and treatment capsules were approved by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA). Written informed consent was obtained from all subjects.</p></sec><sec><title>Study design</title><p>The study was a double-blind placebo-controlled randomized parallel trial with one week treatment followed by one week wash-out. Subjects were randomizsed into two treatment groups (n&#x02009;=&#x02009;10/group) to receive either ferrous sulphate (200&#x000a0;mg capsules containing 65&#x000a0;mg of iron) or placebo, both to be taken at mealtimes twice daily for 7&#x000a0;days during the treatment period. All subjects were advised that they may suffer black stools, as a normal consequence of intervention, irrespective of whether they were on placebo or oral iron (although placebo had no specific stool-darkener added).Subjects were provided with two seven-day symptom questionnaires (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>) to take home for self-completion, and asked to complete them on a daily basis for 14&#x000a0;days &#x02013; the first 7&#x000a0;days whilst on one of the treatments (i.e. ferrous sulphate or placebo) and the following 7&#x000a0;days during the respective wash-out periods. The symptom diaries were coded and anonymised. Codes were broken only after the raw questionnaire data had been entered into the database.</p></sec><sec><title>Data analysis</title><p>The questionnaire is broken down into different compartments (boxes &#x02018;A&#x02019;-&#x02018;J&#x02019;) for ease of reference in this manuscript (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Although all data were collected, only those from boxes C, H,I and J were analysed and are herein reported in figures, tables and/or text. All statistical analysis was performed using GraphPad Prism version 5.03 for Windows (GraphPad Software, San Diego, California, USA). Results are presented as means with either standard error of mean (SEM) or standard deviation (SD) as described. Unless otherwise stated, differences between treatment and wash-out periods and between ferrous sulphate and placebo were examined using the unpaired <italic>t</italic>-test (two-tailed) with Welch&#x02019;s correction for non-equal variances (level of significance set to <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Where, for the placebo group, there was an absence of an individual symptom (i.e. for heartburn, breathlessness or black stools) comparisons with the ferrous sulphate group were made using the paired <italic>t</italic>-test (two-tailed). The number of black stool movements on each day was compared using the one-way analysis of variance with the Bonferroni post-hoc test to correct for multiple comparisons.</p></sec></sec><sec><title>Results and discussion</title><p>Twenty healthy subjects (10/group) took part in the study. The two study groups were similar in terms of socio-demographic characteristics, age and gender (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). Participants were randomly allocated to the 2 groups (ferrous sulphate or placebo) and asked to complete the gastrointestinal symptom questionnaire every day for 14&#x000a0;days. The completion rate of the symptom questionnaire was 100%. All participants found the symptom questionnaire easy to complete but some suggested that a &#x02018;comments&#x02019; section be included so that they could, at times, provide reasons for responses. The average time for completion of the questionnaire was less than 5&#x000a0;minutes per day. Compliance with oral iron/placebo was &#x0003e;80% for the morning dose and &#x0003e;90% for the evening dose for participants in both groups and did not differ between groups. Reasons provided for non-compliance were unrelated to the study treatments.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline socio-demographic data for the participants in the 2 study groups</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center"><bold>Iron group (n&#x02009;=&#x02009;10)</bold></th><th align="center"><bold>Placebo group (n&#x02009;=&#x02009;10)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (years)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;Mean (SD)<hr/></td><td align="center" valign="bottom">32.2 (10.4)<hr/></td><td align="center" valign="bottom">31.7 (10.8)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;Range<hr/></td><td align="center" valign="bottom">21-58<hr/></td><td align="center" valign="bottom">22-59<hr/></td></tr><tr><td align="left" valign="bottom">Gender [n]<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Male</italic><hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">4<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Female</italic><hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">6<hr/></td></tr><tr><td align="left" valign="bottom">Highest education level [n (%)]<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>GCSE</italic><hr/></td><td align="center" valign="bottom">1 (10)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>A level</italic><hr/></td><td align="center" valign="bottom">2 (20)<hr/></td><td align="center" valign="bottom">4 (40)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>First degree or professional qualification</italic><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">4 (40)<hr/></td><td align="center" valign="bottom">3 (30)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Higher degree</italic><hr/></td><td align="center" valign="bottom">3 (30)<hr/></td><td align="center" valign="bottom">3 (30)<hr/></td></tr><tr><td align="left" valign="bottom">Job title [n (%)]<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Undergraduate student</italic><hr/></td><td align="center" valign="bottom">4 (40)<hr/></td><td align="center" valign="bottom">3 (30)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>PhD student</italic><hr/></td><td align="center" valign="bottom">2 (20)<hr/></td><td align="center" valign="bottom">1 (10)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Secretary</italic><hr/></td><td align="center" valign="bottom">1 (10)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Retired teacher</italic><hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">1 (10)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Dietician</italic><hr/></td><td align="center" valign="bottom">3 (30)<hr/></td><td align="center" valign="bottom">2 (20)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02002;<italic>Research fellow</italic><hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">2 (20)<hr/></td></tr><tr><td align="left">&#x02003;&#x02002;<italic>Clinician</italic></td><td align="center">0</td><td align="center">1 (10)</td></tr></tbody></table><table-wrap-foot><p>Differences were not significant between the 2 groups, with <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05.</p></table-wrap-foot></table-wrap><p>In summary, a total of 12 (out of 20) participants reported the presence of one or more symptom(s) in the first week of the study (i.e. during treatment), of which 9 (75%) were in the ferrous sulphate group. In the second week of the study (i.e. wash-out), 9 participants reported one or more symptom(s), of which 6 (67%) were in the ferrous sulphate group. The degree of discomfort caused by each symptom was categorised into mild, moderate or severe as defined in box &#x02018;C&#x02019; of the questionnaire (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Detailed analyses were as follows: in the first week of the study (treatment) the number of symptoms reported per participant in the ferrous sulphate group (mean&#x02009;=&#x02009;6.7, SEM&#x02009;=&#x02009;1.7) was significantly higher than that reported per participant in the placebo group (mean&#x02009;=&#x02009;1.2, SEM&#x02009;=&#x02009;0.5) (<italic>p</italic>&#x02009;=&#x02009;0.01). In the second week of the study (wash-out) the number of symptoms reported per participant in the ferrous sulphate group (mean&#x02009;=&#x02009;4.6, SEM&#x02009;=&#x02009;2.0) tended to be higher than that per participant in the placebo group (mean&#x02009;=&#x02009;1.0, SEM&#x02009;=&#x02009;0.7) but this did not reach significance (<italic>p</italic>&#x02009;=&#x02009;0.12) (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Mean (SEM) incidence per participant of symptoms, from &#x02018;box C&#x02019; of the questionnaire, in in week 1 (treatment) and week 2 (wash-out) of the iron and placebo groups.</bold> The mean incidence of symptoms for the week as mild (stripped part of columns), moderate (closed) and severe (open) is shown.</p></caption><graphic xlink:href="1471-230X-14-103-2"/></fig><p>Table&#x000a0;<xref ref-type="table" rid="T2">2</xref> shows the reported frequency for individual symptoms by the participants in the ferrous sulphate and placebo groups during the treatment and wash-out periods. Adverse events for which the gastrointestinal symptom questionnaire was most discriminatory between ferrous sulphate and placebo groups were: heartburn, abdominal pain and the presence of black stools (all <italic>p</italic>&#x02009;&#x02264;&#x02009;0.03) (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). The differences observed in nausea, constipation and change in bowel movements between the ferrous sulphate and placebo groups may be clinically significant but, due to the small sample size, did not reach statistical significance (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). The number of participants in each group reporting these individual symptoms is presented in Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>A, for both treatment and wash-out weeks. Vomiting was not reported by participants in either group on any day. Overall, the number of participants reporting symptoms in the iron group was significantly higher than the number of participants reporting symptoms in the placebo group (<italic>p</italic>&#x02009;=&#x02009;0.01). The nature of the symptoms reported in the oral iron group is not surprising as iron that remains soluble in the intestinal lumen is likely to be bioavailable but, equally, may be available for other processes including uptake by commensal flora and colonic epithelial cells, and facile redox-cycling in the gut lumen. Indeed, the generation of harmful free-radicals through Fenton chemistry which can cause inflammation and oxidative stress in the intestinal mucosa has been linked to available luminal iron in several studies [<xref ref-type="bibr" rid="B53">53</xref>-<xref ref-type="bibr" rid="B55">55</xref>]. Furthermore, detrimental changes to the commensal microbiota have recently been reported with oral iron supplementation and may be partly responsible for the distal symptoms such as constipation and diarrhoea [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B56">56</xref>].</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Frequency of individual symptoms irrespective of whether mild, moderate or severe (days per week)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>Iron</bold><hr/></th><th colspan="2" align="center" valign="bottom"><bold>Placebo</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th></tr><tr><th align="left"><bold>Symptom</bold></th><th align="center"><bold>
<italic>Treatment</italic>
</bold></th><th align="center"><bold>
<italic>Wash-out</italic>
</bold></th><th align="center"><bold>
<italic>Treatment</italic>
</bold></th><th align="center"><bold>
<italic>Wash-out</italic>
</bold></th><th align="center"><bold>
<italic>p </italic>
</bold><bold>value</bold><sup>
<bold>#</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top"><bold>Nausea</bold><hr/></td><td align="center" valign="bottom">1.1&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="center" valign="bottom">0.1&#x02009;&#x000b1;&#x02009;0.1<hr/></td><td align="center" valign="bottom">0.2&#x02009;&#x000b1;&#x02009;0.1<hr/></td><td align="center" valign="bottom">0.4&#x02009;&#x000b1;&#x02009;0.4<hr/></td><td rowspan="2" align="center" valign="top">0.2<hr/></td></tr><tr><td align="center" valign="bottom">(&#x02212;0.3; 2.5)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.3)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.5)<hr/></td><td align="center" valign="bottom">(&#x02212;0.5; 1.3)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Heartburn</bold><hr/></td><td align="center" valign="bottom">1.0&#x02009;&#x000b1;&#x02009;0.4<hr/></td><td align="center" valign="bottom">0.3&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">0<hr/></td><td rowspan="2" align="center" valign="top">0.03<hr/></td></tr><tr><td align="center" valign="bottom">(0.1; 1.9)<hr/></td><td align="center" valign="bottom">(&#x02212;0.4; 1.0)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Abdominal pain</bold><hr/></td><td align="center" valign="bottom">2.0&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="center" valign="bottom">1.0&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="center" valign="bottom">0.2&#x02009;&#x000b1;&#x02009;0.1<hr/></td><td align="center" valign="bottom">0<hr/></td><td rowspan="2" align="center" valign="top">0.02<hr/></td></tr><tr><td align="center" valign="bottom">(0.5; 3.5)<hr/></td><td align="center" valign="bottom">(&#x02212;0.7; 2.7)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.5)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Headache</bold><hr/></td><td align="center" valign="bottom">1.1&#x02009;&#x000b1;&#x02009;0.5<hr/></td><td align="center" valign="bottom">1.6&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="center" valign="bottom">0.2&#x02009;&#x000b1;&#x02009;0.2<hr/></td><td align="center" valign="bottom">0.1&#x02009;&#x000b1;&#x02009;0.1<hr/></td><td rowspan="2" align="center" valign="top">0.15<hr/></td></tr><tr><td align="center" valign="bottom">(&#x02212;0.1; 2.3)<hr/></td><td align="center" valign="bottom">(0.2; 3.0)<hr/></td><td align="center" valign="bottom">(&#x02212;0.3; 0.7)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.3)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Breathlessness</bold><hr/></td><td align="center" valign="bottom">0.1&#x02009;&#x000b1;&#x02009;0.1<hr/></td><td align="center" valign="bottom">0.5&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">0.1&#x02009;&#x000b1;&#x02009;0.1<hr/></td><td rowspan="2" align="center" valign="top">0.3<hr/></td></tr><tr><td align="center" valign="bottom">(&#x02212;0.1; 0.3)<hr/></td><td align="center" valign="bottom">(&#x02212;0.3; 1.3)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.3)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Diarrohea</bold><hr/></td><td align="center" valign="bottom">0.4&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="center" valign="bottom">0.3&#x02009;&#x000b1;&#x02009;0.2<hr/></td><td align="center" valign="bottom">0.3&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="center" valign="bottom">0.4&#x02009;&#x000b1;&#x02009;0.2<hr/></td><td rowspan="2" align="center" valign="top">0.8<hr/></td></tr><tr><td align="center" valign="bottom">(&#x02212;0.3; 1.1)<hr/></td><td align="center" valign="bottom">(&#x02212;0.2; 0.8)<hr/></td><td align="center" valign="bottom">(&#x02212;0.4; 1.0)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.9)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Constipation</bold><hr/></td><td align="center" valign="bottom">1.0&#x02009;&#x000b1;&#x02009;0.6<hr/></td><td align="center" valign="bottom">0.7&#x02009;&#x000b1;&#x02009;0.5<hr/></td><td align="center" valign="bottom">0.2&#x02009;&#x000b1;&#x02009;0.2<hr/></td><td align="center" valign="bottom">0<hr/></td><td rowspan="2" align="center" valign="top">0.2<hr/></td></tr><tr><td align="center" valign="bottom">(&#x02212;0.3; 2.3)<hr/></td><td align="center" valign="bottom">(&#x02212;0.4; 1.8)<hr/></td><td align="center" valign="bottom">(&#x02212;0.3; 0.7)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Change bowel movements</bold><hr/></td><td align="center" valign="bottom">1.3&#x02009;&#x000b1;&#x02009;0.5<hr/></td><td align="center" valign="bottom">1.5&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="center" valign="bottom">0.4&#x02009;&#x000b1;&#x02009;0.3<hr/></td><td align="center" valign="bottom">0.4&#x02009;&#x000b1;&#x02009;0.2<hr/></td><td rowspan="2" align="center" valign="top">0.15<hr/></td></tr><tr><td align="center" valign="bottom">(0.1; 2.5)<hr/></td><td align="center" valign="bottom">(0.7; 2.3)<hr/></td><td align="center" valign="bottom">(&#x02212;0.2; 1.0)<hr/></td><td align="center" valign="bottom">(&#x02212;0.1; 0.9)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><bold>Black stools</bold><hr/></td><td align="center" valign="bottom">4.1&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="center" valign="bottom">1.3&#x02009;&#x000b1;&#x02009;0.4<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">0<hr/></td><td rowspan="2" align="center" valign="top">0.0004<hr/></td></tr><tr><td align="center" valign="bottom">(2.4; 5.8)<hr/></td><td align="center" valign="bottom">(0.4; 2.2)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td><td align="center" valign="bottom">(0; 0)<hr/></td></tr><tr><td align="left">&#x000a0;</td><td colspan="2" align="center"><italic>p</italic>&#x02009;=&#x02009;0.002</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>Values, derived from boxes &#x02018;C&#x02019; and &#x02018;H&#x02019; of the questionnaire (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>), are shown as mean &#x000b1; standard error (95% confidence interval) for the two groups.</p><p><sup>#</sup>significance value (<italic>p</italic> &#x0003c; 0.05) between the frequency of each symptom for the Iron treatment period versus the Placebo treatment period.</p></table-wrap-foot></table-wrap><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Incidence of individual symptoms in the iron and placebo groups. A</bold>, percentage of participants in each group reporting nausea, heartburn, abdominal pain (ABD pain), constipation, change in bowel movements (Bowel mov) or the presence of black stool movements on at least one day of each week of the intervention or wash-out periods (i.e. data from boxes &#x02018;C&#x02019; and &#x02018;H&#x02019; on the questionnaire (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>)). The number of participants reporting symptoms in the iron group was significantly higher than that of the placebo group (<italic>p</italic> = 0.01). <bold>B</bold>, mean number of black bowel movements per day, obtained from box &#x02018;H&#x02019; of the questionnaire (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>), in the iron group (no black bowel movements were reported in the placebo group). Error bars represent standard error of mean (SEM). *<italic>p</italic> &#x0003c; 0.05; **<italic>p</italic> &#x0003c; 0.01 for comparison between each treatment day and the baseline (i.e. day 0). <sup>##</sup><italic>p</italic> &#x0003c; 0.01 for comparison between each wash-out day and the end of the treatment period (i.e. day 7).</p></caption><graphic xlink:href="1471-230X-14-103-3"/></fig><p>Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>B shows the number of black stool movements reported in the ferrous sulphate group: no black stools were reported by participants in the placebo group. For those participants taking ferrous sulphate there was a significant increase in the number of black stool movements from day 3 of the treatment period (<italic>p</italic>&#x02009;=&#x02009;0.03) which only returned to baseline 3&#x000a0;days after stopping the ferrous sulphate tablets (i.e. day 10 of the study) (<italic>p</italic>&#x02009;=&#x02009;0.005) (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>B). Although subjects were not aware of which group they were in (i.e. treatment or placebo), the presence of black stools could have provided an indication of their randomisation to oral iron. It is thus important to note that symptoms were being reported in the ferrous sulphate group from the first day (for example nausea and abdominal pain) and this was before the onset of black stools which was significant at 72&#x000a0;hours.</p><p>The blackening of stools following oral iron supplementation is derived from the reaction of hydrogen sulphide produced by commensal bacteria, such as sulphate-reducing bacteria, with ferrous iron (Fe<sup>2+</sup>) to produce iron sulphide (FeS). Sulphate-reducing bacteria are a group of &#x02018;emerging pathogens&#x02019; in the colon. These bacteria have an exceptionally high requirement for iron and use sulphur or sulphate, which are plentiful in the colon from the digestion of foods, as electron acceptors during anaerobic respiration, for the oxidative metabolism of organic compounds and H<sub>2</sub>[<xref ref-type="bibr" rid="B57">57</xref>]. Indeed, Werner et al. have shown that numbers of <italic>Desulfovibrio</italic> (the main sulphate-reducing bacteria found in faeces) significantly increased following ferrous sulphate supplementation [<xref ref-type="bibr" rid="B28">28</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>A short and simple-to-answer gastrointestinal symptom questionnaire was developed as a tool to measure adverse-effects for use in intervention studies with oral iron and especially when ferrous sulphate comprises one study arm. The present small study aimed to show where the questionnaire had discriminatory power: i.e. which symptoms are more sensitive to oral ferrous sulphate therapy. The questionnaire was filled in by the study participants during the 7-days of the treatment period and the 7-days of the wash-out period and was discriminant in the total number of reported symptoms per participant between the iron and the placebo groups. Additionally, it showed that the individual symptoms that were significantly more sensitive to the oral iron treatment were heartburn, abdominal pain and the presence of black stools. Although there has been concern that black stools caused by oral iron may mask black stools caused by gastrointestinal blood loss, it is not per se an adverse-effect related to symptoms but, rather, it represents the formation of iron sulphide in the colon due to bacterial activity. However, it could be useful as a marker of the change in bacterial flora (i.e. an increase in sulphate-reducing bacteria at the expense of beneficial bacterial genus such as lactobacilli) in future intervention studies with oral iron and this could be further investigated.</p><p>Despite the uncomplicated format of the questionnaire, a large amount of data is generated. For example, in this small study, 20 participants provided 14&#x000a0;days of questionnaire each (i.e. 280 questionnaires) with 28 pieces of information per questionnaire: this represents 7,840 pieces of data recorded, for most, in a categorical format, for some in a binary form, and for others in a continuous format.</p><p>To facilitate analysis, the main outcomes were restricted to binary events (e.g. presence and absence of symptoms), and the categorisation of their severity was only focussed on data collected from boxes C, H and I of the questionnaire. Clearly, in future studies that utilise this questionnaire, researchers will need to determine whether (a) they collect all data or simplify the questionnaire even further so that only C, H and I are used and (b) if they collect all, how it should be best analysed.Finally, whether the whole questionnaire (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>) is used, or a short version with only boxes C, H and I, a comments box may be a useful addition for patients/participants to provide detail that may inform upon their responses.</p></sec><sec><title>Competing interests</title><p>The authors declare no conflict of interest but DIAP and JJP wish to note that they are co-inventors on a patent detailing novel Fe(III) poly oxo-hydroxide structures that may have potential as dietary supplements and that they consult to Iron Therapeutics UK Limited for advice on their novel oral iron therapeutic.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MCEL and JJP designed the research; MCEL conducted the research; DIAP and SMI analysed data; DIAP, SMI and JJP wrote the paper; DIAP and JJP had primary responsibility for final content. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-230X/14/103/prepub">http://www.biomedcentral.com/1471-230X/14/103/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>We thank Natasha Vidas for her assistance with the human study. The authors would like to thank the UK Medical Research Council (MRC) (U105960399), for funding part of this work. This work is a publication of the UK Medical Research Council.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="book"><collab>WHO</collab><source>The Global Burden of Disease: 2004 Update</source><year>2008</year><publisher-name>Geneva: WHO</publisher-name><fpage>1</fpage><lpage>146</lpage></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="book"><collab>WHO</collab><source>The World Health Report. Reducing Risks, Promoting Healthy Life</source><year>2002</year><publisher-name>Geneva: WHO</publisher-name></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Vander Hoorn</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>CJ</given-names></name><article-title>Selected major risk factors and global and regional burden of disease</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1347</fpage><lpage>1360</lpage><pub-id pub-id-type="pmid">12423980</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="book"><collab>Joint Formulary Committee</collab><source>British National Formulary</source><year>2014</year><publisher-name>London: British Medical Association: Pharmaceutical Society of Great Britain</publisher-name></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>de Souza</surname><given-names>AI</given-names></name><name><surname>Batista Filho</surname><given-names>M</given-names></name><name><surname>Bresani</surname><given-names>CC</given-names></name><name><surname>Ferreira</surname><given-names>LO</given-names></name><name><surname>Figueiroa</surname><given-names>JN</given-names></name><article-title>Adherence and side effects of three ferrous sulfate treatment regimens on anemic pregnant women in clinical trials</article-title><source>Cad Saude Publica</source><year>2009</year><volume>25</volume><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">19503953</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Milman</surname><given-names>N</given-names></name><name><surname>Byg</surname><given-names>KE</given-names></name><name><surname>Bergholt</surname><given-names>T</given-names></name><name><surname>Eriksen</surname><given-names>L</given-names></name><article-title>Side effects of oral iron prophylaxis in pregnancy&#x02013;myth or reality?</article-title><source>Acta Haematol</source><year>2006</year><volume>115</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16424650</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Galloway</surname><given-names>R</given-names></name><name><surname>McGuire</surname><given-names>J</given-names></name><article-title>Determinants of compliance with iron supplementation: supplies, side effects, or psychology?</article-title><source>Soc Sci Med</source><year>1994</year><volume>39</volume><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">7939855</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>de Silva</surname><given-names>AD</given-names></name><name><surname>Tsironi</surname><given-names>E</given-names></name><name><surname>Feakins</surname><given-names>RM</given-names></name><name><surname>Rampton</surname><given-names>DS</given-names></name><article-title>Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">16305723</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Idoate Gastearena</surname><given-names>MA</given-names></name><name><surname>Gil</surname><given-names>AG</given-names></name><name><surname>Azqueta</surname><given-names>A</given-names></name><name><surname>Coronel</surname><given-names>MP</given-names></name><name><surname>Gimeno</surname><given-names>M</given-names></name><article-title>A comparative study on the gastroduodenal tolerance of different antianaemic preparations</article-title><source>Hum Exp Toxicol</source><year>2003</year><volume>22</volume><fpage>137</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">12723894</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="book"><name><surname>Mohamed</surname><given-names>HJ</given-names></name><name><surname>Vidas</surname><given-names>N</given-names></name><name><surname>Mudway</surname><given-names>IS</given-names></name><name><surname>Liu</surname><given-names>DY</given-names></name><name><surname>Geissler</surname><given-names>CA</given-names></name><name><surname>Powell</surname><given-names>JJ</given-names></name><name><surname>Lomer</surname><given-names>MC</given-names></name><article-title>Oral ferrous sulphate tolerance study in healthy individuals (Poster)</article-title><source>TEMA 12 Symposium</source><year>2005</year><publisher-name>Northern Ireland, UK: University of Ulster at Coleraine</publisher-name></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Sazawal</surname><given-names>S</given-names></name><name><surname>Black</surname><given-names>RE</given-names></name><name><surname>Ramsan</surname><given-names>M</given-names></name><name><surname>Chwaya</surname><given-names>HM</given-names></name><name><surname>Stoltzfus</surname><given-names>RJ</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name><name><surname>Dhingra</surname><given-names>U</given-names></name><name><surname>Kabole</surname><given-names>I</given-names></name><name><surname>Deb</surname><given-names>S</given-names></name><name><surname>Othman</surname><given-names>MK</given-names></name><name><surname>Kabole</surname><given-names>FM</given-names></name><article-title>Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">16413877</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Drakesmith</surname><given-names>H</given-names></name><name><surname>Prentice</surname><given-names>A</given-names></name><article-title>Viral infection and iron metabolism</article-title><source>Nat Rev Microbiol</source><year>2008</year><volume>6</volume><fpage>541</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">18552864</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>JF</given-names></name><name><surname>Kurtis</surname><given-names>JD</given-names></name><name><surname>Kabyemela</surname><given-names>ER</given-names></name><name><surname>Fried</surname><given-names>M</given-names></name><name><surname>Duffy</surname><given-names>PE</given-names></name><article-title>The iron trap: iron, malaria and anemia at the mother-child interface</article-title><source>Microbes Infect</source><year>2009</year><volume>11</volume><fpage>460</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">19285567</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><collab>WHO</collab><article-title>Conclusions and recommendations of the WHO Consultation on prevention and control of iron deficiency in infants and young children in malaria-endemic areas</article-title><source>Food Nutr Bull</source><year>2007</year><volume>28</volume><fpage>S621</fpage><lpage>S627</lpage><pub-id pub-id-type="pmid">18297899</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="other"><article-title>GP prescribing data</article-title><comment>[<ext-link ext-link-type="uri" xlink:href="http://www.hscic.gov.uk/gpprescribingdata">http://www.hscic.gov.uk/gpprescribingdata</ext-link>]</comment></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ruivard</surname><given-names>M</given-names></name><name><surname>Feillet-Coudray</surname><given-names>C</given-names></name><name><surname>Rambeau</surname><given-names>M</given-names></name><name><surname>Gerbaud</surname><given-names>L</given-names></name><name><surname>Mazur</surname><given-names>A</given-names></name><name><surname>Rayssiguier</surname><given-names>Y</given-names></name><name><surname>Philippe</surname><given-names>P</given-names></name><name><surname>Coudray</surname><given-names>C</given-names></name><article-title>Effect of daily versus twice weekly long-term iron supplementation on iron absorption and status in iron-deficient women: a stable isotope study</article-title><source>Clin Biochem</source><year>2006</year><volume>39</volume><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">16603147</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Siddiqui</surname><given-names>IA</given-names></name><name><surname>Rahman</surname><given-names>MA</given-names></name><name><surname>Jaleel</surname><given-names>A</given-names></name><article-title>Efficacy of daily vs. weekly supplementation of iron in schoolchildren with low iron status</article-title><source>J Trop Pediatr</source><year>2004</year><volume>50</volume><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">15510758</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Fischer Walker</surname><given-names>CL</given-names></name><name><surname>Baqui</surname><given-names>AH</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Zaman</surname><given-names>K</given-names></name><name><surname>El Arifeen</surname><given-names>S</given-names></name><name><surname>Begum</surname><given-names>N</given-names></name><name><surname>Yunus</surname><given-names>M</given-names></name><name><surname>Black</surname><given-names>RE</given-names></name><name><surname>Caulfield</surname><given-names>LE</given-names></name><article-title>Low-dose weekly supplementation of iron and/or zinc does not affect growth among Bangladeshi infants</article-title><source>Eur J Clin Nutr</source><year>2009</year><volume>63</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17882136</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Hyder</surname><given-names>SM</given-names></name><name><surname>Persson</surname><given-names>LA</given-names></name><name><surname>Chowdhury</surname><given-names>AM</given-names></name><name><surname>Ekstrom</surname><given-names>EC</given-names></name><article-title>Do side-effects reduce compliance to iron supplementation? A study of daily- and weekly-dose regimens in pregnancy</article-title><source>J Health Popul Nutr</source><year>2002</year><volume>20</volume><fpage>175</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">12186198</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Stoltzfus</surname><given-names>RJ</given-names></name><name><surname>Chway</surname><given-names>HM</given-names></name><name><surname>Montresor</surname><given-names>A</given-names></name><name><surname>Tielsch</surname><given-names>JM</given-names></name><name><surname>Jape</surname><given-names>JK</given-names></name><name><surname>Albonico</surname><given-names>M</given-names></name><name><surname>Savioli</surname><given-names>L</given-names></name><article-title>Low dose daily iron supplementation improves iron status and appetite but not anemia, whereas quarterly anthelminthic treatment improves growth, appetite and anemia in Zanzibari preschool children</article-title><source>J Nutr</source><year>2004</year><volume>134</volume><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">14747671</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Makrides</surname><given-names>M</given-names></name><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Gibson</surname><given-names>RA</given-names></name><name><surname>Gibson</surname><given-names>RS</given-names></name><name><surname>Skeaff</surname><given-names>CM</given-names></name><article-title>Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>78</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">12816784</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Shatrugna</surname><given-names>V</given-names></name><name><surname>Raman</surname><given-names>L</given-names></name><name><surname>Kailash</surname><given-names>U</given-names></name><name><surname>Balakrishna</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>KV</given-names></name><article-title>Effect of dose and formulation on iron tolerance in pregnancy</article-title><source>Natl Med J India</source><year>1999</year><volume>12</volume><fpage>18</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">10326325</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Little</surname><given-names>BB</given-names></name><article-title>Pharmacokinetics during pregnancy: evidence-based maternal dose formulation</article-title><source>Obstet Gynecol</source><year>1999</year><volume>93</volume><fpage>858</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">10912434</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Hutchinson</surname><given-names>C</given-names></name><name><surname>Al-Ashgar</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>DY</given-names></name><name><surname>Hider</surname><given-names>RC</given-names></name><name><surname>Powell</surname><given-names>JJ</given-names></name><name><surname>Geissler</surname><given-names>CA</given-names></name><article-title>Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron</article-title><source>Eur J Clin Invest</source><year>2004</year><volume>34</volume><fpage>782</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">15530152</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Erichsen</surname><given-names>K</given-names></name><name><surname>Ulvik</surname><given-names>RJ</given-names></name><name><surname>Grimstad</surname><given-names>T</given-names></name><name><surname>Berstad</surname><given-names>A</given-names></name><name><surname>Berge</surname><given-names>RK</given-names></name><name><surname>Hausken</surname><given-names>T</given-names></name><article-title>Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>831</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">16225492</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>P</given-names></name><name><surname>Halliwell</surname><given-names>B</given-names></name><article-title>Micronutrients: oxidant/antioxidant status</article-title><source>Br J Nutr</source><year>2001</year><volume>85</volume><issue>Suppl 2</issue><fpage>S67</fpage><lpage>S74</lpage><pub-id pub-id-type="pmid">11509092</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Dostal</surname><given-names>A</given-names></name><name><surname>Chassard</surname><given-names>C</given-names></name><name><surname>Hilty</surname><given-names>FM</given-names></name><name><surname>Zimmermann</surname><given-names>MB</given-names></name><name><surname>Jaeggi</surname><given-names>T</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Lacroix</surname><given-names>C</given-names></name><article-title>Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats</article-title><source>J Nutr</source><year>2012</year><volume>142</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">22190022</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Werner</surname><given-names>T</given-names></name><name><surname>Wagner</surname><given-names>SJ</given-names></name><name><surname>Martinez</surname><given-names>I</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Clavel</surname><given-names>T</given-names></name><name><surname>Kisling</surname><given-names>S</given-names></name><name><surname>Schuemann</surname><given-names>K</given-names></name><name><surname>Haller</surname><given-names>D</given-names></name><article-title>Depletion of luminal iron alters the gut microbiota and prevents Crohn&#x02019;s disease-like ileitis</article-title><source>Gut</source><year>2011</year><volume>60</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">21076126</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Zimmermann</surname><given-names>MB</given-names></name><name><surname>Chassard</surname><given-names>C</given-names></name><name><surname>Rohner</surname><given-names>F</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>Nindjin</surname><given-names>C</given-names></name><name><surname>Dostal</surname><given-names>A</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Ghattas</surname><given-names>H</given-names></name><name><surname>Lacroix</surname><given-names>C</given-names></name><name><surname>Hurrell</surname><given-names>RF</given-names></name><article-title>The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d&#x02019;Ivoire</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>92</volume><fpage>1406</fpage><lpage>1415</lpage><pub-id pub-id-type="pmid">20962160</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Crane</surname><given-names>SJ</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><article-title>Chronic gastrointestinal symptoms in the elderly</article-title><source>Clin Geriatr Med</source><year>2007</year><volume>23</volume><fpage>721</fpage><lpage>734</lpage><comment>v</comment><pub-id pub-id-type="pmid">17923334</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Kearney</surname><given-names>DJ</given-names></name><name><surname>McDermott</surname><given-names>K</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>TL</given-names></name><article-title>Association of participation in a mindfulness programme with bowel symptoms, gastrointestinal symptom-specific anxiety and quality of life</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>34</volume><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">21651595</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Jerndal</surname><given-names>P</given-names></name><name><surname>Ringstrom</surname><given-names>G</given-names></name><name><surname>Agerforz</surname><given-names>P</given-names></name><name><surname>Karpefors</surname><given-names>M</given-names></name><name><surname>Akkermans</surname><given-names>LM</given-names></name><name><surname>Bayati</surname><given-names>A</given-names></name><name><surname>Simren</surname><given-names>M</given-names></name><article-title>Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS</article-title><source>Neurogastroenterol Motil</source><year>2010</year><volume>22</volume><fpage>646</fpage><lpage>e179</lpage><pub-id pub-id-type="pmid">20367800</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Portincasa</surname><given-names>P</given-names></name><name><surname>Maggipinto</surname><given-names>A</given-names></name><name><surname>Berardino</surname><given-names>M</given-names></name><name><surname>Bonfrate</surname><given-names>L</given-names></name><name><surname>Costin</surname><given-names>S</given-names></name><name><surname>Todarello</surname><given-names>O</given-names></name><name><surname>Palasciano</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>DQ</given-names></name><name><surname>Dumitrascu</surname><given-names>DL</given-names></name><article-title>Assessing gastrointestinal symptoms and perception, quality of life, motility, and autonomic neuropathy in clinical studies</article-title><source>J Gastrointestin Liver Dis</source><year>2009</year><volume>18</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">19565052</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Jeong</surname><given-names>JJ</given-names></name><name><surname>Choi</surname><given-names>MG</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Oh</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>JM</given-names></name><name><surname>Cho</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>IS</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Choi</surname><given-names>KY</given-names></name><name><surname>Chung</surname><given-names>IS</given-names></name><article-title>Chronic gastrointestinal symptoms and quality of life in the Korean population</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>6388</fpage><lpage>6394</lpage><pub-id pub-id-type="pmid">19009657</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Johnson</surname><given-names>AL</given-names></name><name><surname>Barron</surname><given-names>AC</given-names></name><name><surname>Passo</surname><given-names>MH</given-names></name><name><surname>Griffin</surname><given-names>TA</given-names></name><name><surname>Graham</surname><given-names>TB</given-names></name><name><surname>Lovell</surname><given-names>DJ</given-names></name><article-title>Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire</article-title><source>J Clin Rheumatol</source><year>2005</year><volume>11</volume><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16357756</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Bovenschen</surname><given-names>HJ</given-names></name><name><surname>Laheij</surname><given-names>RJ</given-names></name><name><surname>Tan</surname><given-names>AC</given-names></name><name><surname>Witteman</surname><given-names>EM</given-names></name><name><surname>Rossum</surname><given-names>LG</given-names></name><name><surname>Jansen</surname><given-names>JB</given-names></name><article-title>Health-related quality of life of patients with gastrointestinal symptoms</article-title><source>Aliment Pharmacol Ther</source><year>2004</year><volume>20</volume><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15274668</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Kong</surname><given-names>SX</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><article-title>Gastrointestinal symptoms and health related quality of life in patients with arthritis</article-title><source>J Rheumatol</source><year>2000</year><volume>27</volume><fpage>1373</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">10852256</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Schultink</surname><given-names>W</given-names></name><name><surname>van der Ree</surname><given-names>M</given-names></name><name><surname>Matulessi</surname><given-names>P</given-names></name><name><surname>Gross</surname><given-names>R</given-names></name><article-title>Low compliance with an iron-supplementation program: a study among pregnant women in Jakarta, Indonesia</article-title><source>Am J Clin Nutr</source><year>1993</year><volume>57</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">8424380</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Lutsey</surname><given-names>PL</given-names></name><name><surname>Dawe</surname><given-names>D</given-names></name><name><surname>Villate</surname><given-names>E</given-names></name><name><surname>Valencia</surname><given-names>S</given-names></name><name><surname>Lopez</surname><given-names>O</given-names></name><article-title>Iron supplementation compliance among pregnant women in Bicol, Philippines</article-title><source>Public Health Nutr</source><year>2008</year><volume>11</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">17519048</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Seck</surname><given-names>BC</given-names></name><name><surname>Jackson</surname><given-names>RT</given-names></name><article-title>Determinants of compliance with iron supplementation among pregnant women in Senegal</article-title><source>Public Health Nutr</source><year>2008</year><volume>11</volume><fpage>596</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">17764606</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Veldhuyzen</surname><given-names>SJ</given-names></name><name><surname>Chung</surname><given-names>SA</given-names></name><name><surname>Shapiro</surname><given-names>CM</given-names></name><name><surname>Dhillon</surname><given-names>S</given-names></name><name><surname>Escobedo</surname><given-names>S</given-names></name><name><surname>Chakraborty</surname><given-names>BK</given-names></name><name><surname>Mann</surname><given-names>V</given-names></name><name><surname>Tanser</surname><given-names>L</given-names></name><name><surname>Nevin</surname><given-names>K</given-names></name><article-title>Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test</article-title><source>Can J Gastroenterol</source><year>2005</year><volume>19</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">15997268</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Dimenas</surname><given-names>E</given-names></name><name><surname>Carlsson</surname><given-names>G</given-names></name><name><surname>Glise</surname><given-names>H</given-names></name><name><surname>Israelsson</surname><given-names>B</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><article-title>Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease</article-title><source>Scand J Gastroenterol</source><year>1996</year><volume>31</volume><fpage>8</fpage><lpage>13</lpage></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Dimenas</surname><given-names>E</given-names></name><name><surname>Glise</surname><given-names>H</given-names></name><name><surname>Hallerback</surname><given-names>B</given-names></name><name><surname>Hernqvist</surname><given-names>H</given-names></name><name><surname>Svedlund</surname><given-names>J</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><article-title>Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal-ulcer</article-title><source>Scand J Gastroenterol</source><year>1995</year><volume>30</volume><fpage>1046</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">8578162</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Boyce</surname><given-names>PM</given-names></name><name><surname>Owen</surname><given-names>BK</given-names></name><name><surname>Newman</surname><given-names>P</given-names></name><name><surname>Paterson</surname><given-names>KJ</given-names></name><article-title>Initial validation of a bowel symptom questionnaire and measurement of chronic gastrointestinal symptoms in Australians</article-title><source>Aust N Z J Med</source><year>1995</year><volume>25</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">8540870</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Foster</surname><given-names>JM</given-names></name><name><surname>van der Molen</surname><given-names>T</given-names></name><name><surname>Caeser</surname><given-names>M</given-names></name><name><surname>Hannaford</surname><given-names>P</given-names></name><article-title>The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2008</year><volume>17</volume><fpage>278</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">18300325</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Varma</surname><given-names>MG</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Berian</surname><given-names>JR</given-names></name><name><surname>Patterson</surname><given-names>TR</given-names></name><name><surname>McCrea</surname><given-names>GL</given-names></name><name><surname>Hart</surname><given-names>SL</given-names></name><article-title>The constipation severity instrument: a validated measure</article-title><source>Dis Colon Rectum</source><year>2008</year><volume>51</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">18172725</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Quan</surname><given-names>C</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Cross</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>J</given-names></name><name><surname>Giles</surname><given-names>N</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><article-title>Development and validation of the diabetes bowel symptom questionnaire</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">12752355</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Nappi</surname><given-names>CTG</given-names></name><name><surname>Morra</surname><given-names>I</given-names></name><name><surname>Massaro</surname><given-names>M</given-names></name><name><surname>Formisano</surname><given-names>C</given-names></name><name><surname>Di Carlo</surname><given-names>C</given-names></name><article-title>Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study</article-title><source>Acta Obstet Gynecol Scand</source><year>2009</year><volume>88</volume><fpage>1031</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">19639462</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Sifakis</surname><given-names>S</given-names></name><name><surname>Angelakis</surname><given-names>E</given-names></name><name><surname>Papadopoulou</surname><given-names>E</given-names></name><name><surname>Stratoudakis</surname><given-names>G</given-names></name><name><surname>Fragouli</surname><given-names>Y</given-names></name><name><surname>Koumantakis</surname><given-names>E</given-names></name><article-title>The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy</article-title><source>Clin Exp Obstet Gynecol</source><year>2005</year><volume>32</volume><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">16108396</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Aamodt</surname><given-names>AH</given-names></name><name><surname>Stovner</surname><given-names>LJ</given-names></name><name><surname>Hagen</surname><given-names>K</given-names></name><name><surname>Zwart</surname><given-names>JA</given-names></name><article-title>Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study</article-title><source>Cephalalgia</source><year>2008</year><volume>28</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">18197884</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Spierings</surname><given-names>EL</given-names></name><article-title>Headache of gastrointestinal origin: case studies</article-title><source>Headache</source><year>2002</year><volume>42</volume><fpage>217</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">11903545</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>A</given-names></name><name><surname>Sandstrom</surname><given-names>B</given-names></name><name><surname>Van Amelsvoort</surname><given-names>JM</given-names></name><article-title>The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females</article-title><source>Br J Nutr</source><year>1997</year><volume>78</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">9301412</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Carrier</surname><given-names>J</given-names></name><name><surname>Aghdassi</surname><given-names>E</given-names></name><name><surname>Cullen</surname><given-names>J</given-names></name><name><surname>Allard</surname><given-names>JP</given-names></name><article-title>Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis</article-title><source>J Nutr</source><year>2002</year><volume>132</volume><fpage>3146</fpage><lpage>3150</lpage><pub-id pub-id-type="pmid">12368409</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Lund</surname><given-names>EK</given-names></name><name><surname>Wharf</surname><given-names>SG</given-names></name><name><surname>Fairweather-Tait</surname><given-names>SJ</given-names></name><name><surname>Johnson</surname><given-names>IT</given-names></name><article-title>Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers</article-title><source>Am J Clin Nutr</source><year>1999</year><volume>69</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">9989688</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Orozco</surname><given-names>MN</given-names></name><name><surname>Solomons</surname><given-names>NW</given-names></name><name><surname>Schumann</surname><given-names>K</given-names></name><name><surname>Friel</surname><given-names>JK</given-names></name><name><surname>de Montenegro</surname><given-names>AL</given-names></name><article-title>Antioxidant-rich oral supplements attenuate the effects of oral iron on in situ oxidation susceptibility of human feces</article-title><source>J Nutr</source><year>2010</year><volume>140</volume><fpage>1105</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">20392879</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Kortman</surname><given-names>GA</given-names></name><name><surname>Boleij</surname><given-names>A</given-names></name><name><surname>Swinkels</surname><given-names>DW</given-names></name><name><surname>Tjalsma</surname><given-names>H</given-names></name><article-title>Iron availability increases the pathogenic potential of Salmonella typhimurium and other enteric pathogens at the intestinal epithelial interface</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e29968</fpage><pub-id pub-id-type="pmid">22272265</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Gibson</surname><given-names>GR</given-names></name><article-title>Physiology and ecology of the sulphate-reducing bacteria</article-title><source>J Appl Bacteriol</source><year>1990</year><volume>69</volume><fpage>769</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">2286579</pub-id></mixed-citation></ref></ref-list></back></article>